Response rate to a single dose of vinblastine administered to dogs with treatment‐naive multicentric lymphoma

Harding, Kayla; Bergman, Noelle; Smith, Annette; Lindley, Stephanie E. S.; Szivek, Anna; Milner, Rowan J.; Brawner, William R.; Lejeune, Amandine

doi:10.1111/vco.12433

Cited by 8 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incidence of hospitalisation after chemotherapy varied from 0% to 24% of dogs in literature, 13,27,38,49,51–53,57,60–63,66–70,80,81 which is similar to our study with 23.9% dogs that were hospitalised. Treatment course modifications were performed in 40.0% of dogs in our study and is commonly reported in dogs undergoing chemotherapy.…”

Section: Discussionsupporting

confidence: 90%

“…sAE were observed at least once in 32.3%, which is higher than the figures reported in most studies, varying between 0% and 22.2%. 4,5,13,22,38,[51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70] Only a few studies described a high rate of sAE, between 25% and 71%. [71][72][73][74] The discordance between our results and data available in textbooks and peer-reviewed publications could be explained by several reasons.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Are severe adverse events commonly observed in dogs during cancer chemotherapy? A retrospective study on 155 dogs

Chavalle

Chamel

Denoeux³

et al. 2021

Vet Comparative Oncology

View full text Add to dashboard Cite

Overall prevalence of severe adverse events (sAE) has been poorly studied in veterinary medicine and peer‐reviewed studies mostly focused on a single protocol, making it difficult to have a general overview. The aim of this retrospective study was to assess the frequency and risk factors of sAE secondary to various protocols of chemotherapy in dogs. Medical records of 155 dogs receiving chemotherapy between January 2013 and December 2018 were reviewed. Adverse events (AE) were graded according to Veterinary Comparative Oncology Group‐common terminology criteria for AE (VCOG‐CTCAE) grading system. Statistical analyses were performed to determine whether demographic, cancer type and chemotherapy protocol were associated with development of sAE and their consequences. AE were reported at least once in 124 (80%) dogs and sAE were observed in 50 (32.3%) dogs. Among them, 23 (14.8%) had gastro‐intestinal and 31 (20.0%) had myelotoxic events. sAE led to hospitalisation in 37 (23.9%) dogs, to chemotherapy arrest in 12 (7.7%) dogs and to euthanasia or death in 9 (5.8%) dogs. Haematopoietic tumours were statistically associated with a higher frequency of sAE (p = .004), gastrointestinal sAE (p = .009) and hospitalisation (p = .004). A body weight over 10 kg was associated with less haematological sAE (p < .001). The use of a multi‐agent protocol was highlighted as a risk factor for sAE (p = .038) and haematological sAE (p < .001). sAE following chemotherapy and leading to hospitalisation, chemo arrest or death were relatively common. A special attention during chemotherapy follow‐up should be given to small dogs and those receiving multi‐agent protocol or treated for haematopoietic tumours.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Are severe adverse events commonly observed in dogs during cancer chemotherapy? A retrospective study on 155 dogs

Chavalle

Chamel

Denoeux³

et al. 2021

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…In the present study, gastrointestinal adverse events were mild and self-limited in both groups. Similar findings were also described in previous studies [4,15,21,23].…”

Section: Discussionsupporting

confidence: 93%

“…In that study, dogs were treated with 2 mg/m² doses of VBL while a small subset of dogs were treated with 2.5 mg/m² doses of VBL. Dogs treated with a higher VBL dose had significantly improved response rates, suggesting that an increase in the VBL dose may improve efficacy in some cases [4].…”

Section: Discussionmentioning

confidence: 98%

Comparison of Two Different Vinblastine Dosages for Treatment of Cutaneous Mast Cell Tumor in Dogs

Kluthcovsky

Firmo

Cassino

et al. 2020

Acta Scientiae. Vet.

View full text Add to dashboard Cite

Background: Mast cell tumors (MCT) are among the most common malignant cutaneous neoplasm in dogs with variable biologic behavior and remain a therapeutic challenge in high-grade cases. Surgery remains the primary treatment for canine MCT; however, chemotherapy and radiation therapy are commonly used to treat aggressive cases. The combination of vinblastine (VBL) at a dose of 2 mg/m² and prednisone is the classically described protocol for MCT treatment. Studies have shown the safety of higher VBL doses for dogs with MCT, but there is a lack of information regarding dose intensity and outcome as a goal after chemotherapy. This study aimed to evaluate the impact of a higher dose of VBL on MCT treatment outcome.Materials, Methods & Results: This was an observational and comparative study conducted in two different Veterinary Teaching Hospitals. Client-owned dogs with histopathological diagnosis of grade II or III MCT were selected and underwent at least four chemotherapy sessions with VBL and prednisone. The experimental group (EG) consisted of 18 dogs that received a dose of 3 mg/m² VBL treated in one institution. The control group (CG) included 31 dogs that received a dose of 2 mg/m² VBL treated at the other institution. All dogs treated in both groups had a clinical and complete blood count (CBC) evaluation performed previous the start of chemotherapy (T0) and before each weekly treatment (T1, T2, T3, and T4). After treatment, dogs in both groups were followed-up for the recurrence rate and overall survival time after diagnosis. There was no significant difference in clinical variables between EG and CG. During treatment, dogs of EG showed a significant reduction in erythrocyte, hemoglobin, and hematocrit values between T0 and T1, T2, T3, and T4 (P < 0.001). Comparatively, the CG showed significant reduction in hemoglobin (P = 0.02) and total leucocytes (P = 0.001) values in the same period. Despite these findings, these hematological parameters did not exceed the lower limit for the species in both groups. There was a higher-grade neutropenia one week after the first VBL application (T2) in both groups, with no statistical difference in neutrophil counts at T2 or during the whole treatment. There were discrete and self-limited episodes of anorexia, vomiting, and diarrhea in both groups. After chemotherapy, dogs in EG showed a significantly lower rate of recurrence than dogs in CG (P = 0.02). There was no significant difference in the overall survival time between groups.Discussion: The absence of significant differences in clinical variables (e.g. sex, age, histological grading, and tumor location) between EG and CG suggests that the groups may be similar regarding these parameters. All dogs included in this study had a recommendation for MCT post-operative chemotherapy treatment. VBL action is non-selective and anemia is not a commonly described adverse effect associated with its administration. Despite that, EG dogs exhibited a reduction in erythrocytes, hematocrit, and hemoglobin, and CG dogs in hemoglobin throughout T0 to T4. The highest number of neutropenia episodes occurred during T2, after the first VBL application in both groups with a trend of stabilization after T2, which is compatible with findings described in the literature. Any dog of EG or CG had to interrupt the treatment due to hematological or gastrointestinal toxicity or died during treatment. The role of VBL dose intensity in outcome is still debatable for dogs with MCT, once it is a multifactorial disease with variable presentation. In this study, there was no difference in overall survival time after diagnosis between groups, and EG dogs treated with a higher VBL dose showed significantly less tumor recurrence than CG.

show abstract

“…Additionally, three dogs received drug substitutions as a result of toxicity. Vinblastine was incorporated into the protocol of a single dog as a result of unacceptable GI toxicity to vincristine, despite the questionable efficacy of this agent in dogs with multicentric lymphoma 39,40 . Similarly, a single dog received chlorambucil following development of sterile hemorrhagic cystitis and a single dog received mitoxantrone following the diagnosis of sinus node dysfunction.…”

Section: Discussionmentioning

confidence: 99%

Response‐based modification of CHOP chemotherapy for canine B‐cell lymphoma

Benjamin

Sørenmo

Krick³

et al. 2021

Vet Comparative Oncology

View full text Add to dashboard Cite

Despite high initial response rates, a subset of dogs with B‐cell lymphoma responds less robustly to CHOP‐based chemotherapy and experiences shorter survival. One hundred and four dogs with nodal B‐cell lymphoma were treated with a response‐based CHOP (RBCHOP) protocol modified based on response to individual drugs during the first chemotherapy cycle. Dogs achieving complete (CR) or partial response (PR) at week 3, following treatment with vincristine and cyclophosphamide, received RBCHOP 1 (n = 72), a protocol sequentially rotating vincristine, cyclophosphamide, and doxorubicin. Dogs without a detectable response at week 3 that subsequently achieved CR or PR following treatment with doxorubicin received RBCHOP 2 (n = 14), in which four doses of doxorubicin were given consecutively followed by vincristine and cyclophosphamide. Dogs that failed to respond at week 3 and then to doxorubicin at week 5 assessment were offered rescue chemotherapy (RBCHOP 3, n = 18). Median progression free survival (PFS) and overall survival time (OST) were similar between RBCHOP 1 (PFS 210 days, OST 354 days) and RBCHOP 2 (PFS 220 days, OST 456 days), but significantly shorter for RBCHOP 3 (PFS 34 days, OST 80.5 days, P < 0.001). No presenting signalment nor hematologic variable differentiated patient cohort, however, dogs in RBCHOP 2 and RBCHOP 3 were more likely to have a lymphocytosis at diagnosis (P = 0.02 and 0.04, respectively). Protocol modification based on response during the first cycle resulted in similar toxicity profiles and outcomes to previously published variants of CHOP, and prognosis remained poor for dogs failing to respond during the first treatment cycle.

show abstract

Response rate to a single dose of vinblastine administered to dogs with treatment‐naive multicentric lymphoma

Cited by 8 publications

References 22 publications

Are severe adverse events commonly observed in dogs during cancer chemotherapy? A retrospective study on 155 dogs

Are severe adverse events commonly observed in dogs during cancer chemotherapy? A retrospective study on 155 dogs

Comparison of Two Different Vinblastine Dosages for Treatment of Cutaneous Mast Cell Tumor in Dogs

Response‐based modification of CHOP chemotherapy for canine B‐cell lymphoma

Contact Info

Product

Resources

About